Smith & Nephew expecting a Q4 underlying revenue decline of approximately -7%

Smith & Nephew plc

Smith & Nephew plc (LON:SN), the global medical technology business, has announced that it expects a fourth quarter underlying1 revenue decline of approximately -7%. Sales were impacted by increased rates of COVID-19 infection from mid-October onwards, particularly in the US and Europe where more procedures were postponed following the reintroduction of restrictions.

As in previous months, the impact was most pronounced on our Orthopaedic Reconstruction, Sports Medicine and ENT businesses, driven by lower levels of elective surgery. Our Advanced Wound Management and Trauma businesses remained more resilient.

Full year underlying revenue is expected to have declined approximately
-12%. As previously stated, the trading profit margin will be substantially down year-on-year, with negative operating leverage due to lower volumes partially offset by cost control measures.

Throughout 2020 we continued to serve customers, develop and launch new products and make acquisitions, whilst prioritising the health and wellbeing of employees.

Further detail of the trading performance, including franchise and regional sales performance, trading profit margin, and a review of our strategic progress in 2020, will be provided with Smith & Nephew’s fourth quarter and full year results, scheduled for 18 February 2021.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    Ilika launches £3.8m fundraise including £0.5m Retail Offer

    Ilika Plc has successfully closed its accelerated bookbuild, raising approximately £3.3 million to enhance solid-state battery technology and commercial growth.

    Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

    Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF.

    Likewise grants over 3.1m shares under 2025 SAYE scheme

    Likewise Group plc (LON:LIKE) has successfully closed its 2025 Save As You Earn Scheme, granting options to 69 employees on over 3.1 million shares.

    Zotefoams reports record £50.7m revenue in strong start to 2025

    Zotefoams Plc reports strong sales growth of 8% and record revenue for the first four months of 2025, showcasing a successful strategic pivot into key markets.

    Ilika announces £3.5m fundraise via Placing and Retail Offer

    Ilika Plc, a leader in solid-state battery technology, plans to raise approximately £3.0 million through a new share placing and a retail offer for shareholders.

      Search

      Search